ArticleMolecular cell2021
NINJ1, rupturing swollen membranes for cataclysmic cell lysis.
Article in Molecular cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- NINJ1 plays a vital role in the release of neutrophil extracellular traps during acute lung injury.Cell death & disease · 2026Article
- Characterization of programmed cell death pathways activated in Mycobacterium tuberculosis-infected human macrophages.Cell death discovery · 2026Article
- Ninjurin-1 executes plasma membrane rupture and impairs anti-microbial immunity in an early jawed vertebrate.Cellular and molecular life sciences : CMLS · 2025Article
- Targeting inflammasomes as a therapeutic potential for HIV/AIDS.Cellular and molecular life sciences : CMLS · 2025Review
- Metabolic Inhibition Induces Pyroptosis in Uveal Melanoma.Molecular cancer research : MCR · 2025Article
- Article
- Ninjurin-1 drives atherosclerosis progression viaFrontiers in immunology · 2025Article
- Inducers and Inhibitors of Pyroptotic Death of Granulosa Cells in Models of Premature Ovarian Insufficiency and Polycystic Ovary Syndrome.Reproductive sciences (Thousand Oaks, Calif.) · 2024Review
- The gasdermin family: emerging therapeutic targets in diseases.Signal transduction and targeted therapy · 2024Review
- Elevated Serum Ninjurin-1 Is Associated with a High Risk of Large Artery Atherosclerotic Acute Ischemic Stroke.Translational stroke research · 2023Article
- N,N-Dimethyl-3β-hydroxycholenamide attenuates neuronal death and retinal inflammation in retinal ischemia/reperfusion injury by inhibiting Ninjurin 1.Journal of neuroinflammation · 2023Article
- Gasdermin D membrane pores orchestrate IL-1α secretion from necrotic macrophages after NFS-rich silica exposure.Archives of toxicology · 2023Article
- The double-edged functions of necroptosis.Cell death & disease · 2023Review
- NINJ1 Regulates Platelet Activation and PANoptosis in Septic Disseminated Intravascular Coagulation.International journal of molecular sciences · 2023Article
- The gasdermins: a pore-forming protein family expressed in the epidermis.Frontiers in immunology · 2023Review
- Pyroptosis in Periprosthetic Osteolysis.Biomolecules · 2022Review
- Catching a killer: Mechanisms of programmed cell death and immune activation in Amyotrophic Lateral Sclerosis.Immunological reviews · 2022Review
- The Role of Peroxiredoxins in the Regulation of Sepsis.Antioxidants (Basel, Switzerland) · 2022Review
- Differential Expression and Copy Number Variation of Gasdermin (GSDM) Family Members, Pore-Forming Proteins in Pyroptosis, in Normal and Malignant Serous Ovarian Tissue.Inflammation · 2021Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using a forward-genetic screening of macrophages from randomly mutagenized mice, Kayagaki et al. (2021) identify NINJ1 that mediates plasma membrane rupture following various types of programmed cell death, an event previously thought to be passive.
Indexed as
Identifiers
33798414What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.